Molecular Partners is developing innovative therapies from the DARPin platform. DARPins display exceptional potency, adjustable pharmacological properties and can be rapidly developed. This next generation of protein therapeutics can add transforming treatment options beyond the currently available.
The proprietary DARPin product engine led to the discovery of MP0112, our lead product. MP0112 has completed Phase I/IIa clinical trials in two indications in ophthalmology. Further compounds are in preclinical development and late stage research in oncology, inflammation and other therapeutic areas. In addition to our fully owned drug candidates, several DARPins are being developed in partnership with major biopharmaceutical companies.